中国医院用药评价与分析2025，Vol.25Issue(4)：453-457,5.DOI:10.14009/j.issn.1672-2124.2025.04.016
戈舍瑞林联合比卡鲁胺用于前列腺癌术后的疗效及安全性的Meta分析
Meta-Analysis on Efficacy and Safety of Goserelin Combined with Gicalutamide in the Treatment of Postoperative Prostate Cancer
摘要
Abstract
OBJECTIVE:To systematically evaluate the efficacy and safety of goserelin combined with bicalutamide in the treatment of prostate cancer,and to provide evidence-based evidence for clinical treatment of prostate cancer patients.METHODS:CNKI,Wanfang Data,VIP,CBM,Embase,PubMed,Web of Science,and the Cochrane Library were retrieved to collect randomized controlled trials of goserelin combined with bicalutamide in the treatment of prostate cancer(the combination group was treated with goserelin combined with bicalutamide,while the control group received bicalutamide alone).The retrieval time was from the establishment of the database to Oct.2024.Meta-analysis was performed by using RevMan 5.4.1 software.Outcome indicators included total clinical effective rate,serum levels of prostate-specific antigen(PSA),free prostate-specific antigen(f-PSA),vascular endothelial growth factor(VEGF)and α-formyl-assisted A racemase(P504S),and the incidence of adverse drug reactions.RESULTS:Totally 8 randomized controlled trials were retrieved,including 602 patients(301 patients in combination group and 301 patients in control group).Meta-analysis showed that,compared with bicalutamide alone,goserelin combined with bicalutamide could improve the clinical total effective rate(OR=3.85,95%CI=2.43-6.10,P<0.000 01),significantly reduce the serum PSA level(MD=-6.74,95%CI=-9.99--3.49,P<0.000 1),f-PSA level(MD=-1.27,95%CI=-1.72--0.81,P<0.000 01),and P504S level(MD=-0.64,95%CI=-0.70--0.59,P<0.000 01),with statistically significant differences.Goserelin combined with bicalutamide could reduce the VEGF level,but the difference was not statistically significant compared to the use of bicalutamide alone(MD=-131.53,95%CI=-281.69-18.64,P=0.09).There was no significant difference in the incidence of adverse drug reactions between two groups(P>0.05).In this study,the funnel plot was asymmetric and publication bias was considered.CONCLUSIONS:Meta-analysis results suggest that the efficacy and safety of goserrelin combined with bicalutamide in the treatment of postoperative prostate cancer are significant.关键词
戈舍瑞林/比卡鲁胺/前列腺癌/总有效率/Meta分析Key words
Goserelin/Bicalutamide/Prostate cancer/Total effective rate/Meta-analysis分类
医药卫生引用本文复制引用
盛国楼,张林玲,黄培艳,杭永付..戈舍瑞林联合比卡鲁胺用于前列腺癌术后的疗效及安全性的Meta分析[J].中国医院用药评价与分析,2025,25(4):453-457,5.基金项目
白求恩公益基金会"2024耀动神州-药学科研能力建设基金项目"(No.05018) （No.05018）
江苏省医学重点学科(No.ZDXK202247) （No.ZDXK202247）
